Results of the CheckMate 816 clinical trial showed that neoadjuvant nivolumab+ chemotherapy prolonged EFS and increased the pCR rate of NSCLC patients in the subgroup with PD-L1 expression level ≥1% (EFS:21.1 months vs. 18.4 months; pCR:32.6% vs. 16.7%) [22]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.